JO
CRSP icon

John Overdeck’s CRISPR Therapeutics CRSP Stock Holding History

John Overdeck’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108M Buy
1,988,621
+505,570
+34% +$26.6M 0.08% 291
2026
Q1 		$70.5M Buy
1,483,051
+1,012,430
+215% +$53.4M 0.06% 378
2025
Q4 		$24.7M Sell
470,621
-574,068
-55% -$34.4M 0.03% 623
2025
Q3 		$67.7M Sell
1,044,689
-501,277
-32% -$28.8M 0.1% 258
2025
Q2 		$75.2M Buy
1,545,966
+356,807
+30% +$13.8M 0.13% 199
2025
Q1 		$40.5M Buy
1,189,159
+882,887
+288% +$37.4M 0.09% 280
2024
Q4 		$12.1M Buy
306,272
+127,219
+71% +$6.01M 0.03% 670
2024
Q3 		$8.41M Buy
179,053
+161,994
+950% +$8.22M 0.02% 839
2024
Q2 		$921K Sell
17,059
-31,999
-65% -$1.85M ﹤0.01% 2030
2024
Q1 		$3.34M Sell
49,058
-35,973
-42% -$2.58M 0.01% 1186
2023
Q4 		$5.32M Sell
85,031
-134,756
-61% -$7.45M 0.01% 958
2023
Q3 		$9.98M Sell
219,787
-213,284
-49% -$11M 0.03% 606
2023
Q2 		$24.3M Buy
433,071
+217,037
+100% +$12.3M 0.06% 358
2023
Q1 		$9.77M Buy
216,034
+174,303
+418% +$8.47M 0.03% 595
2022
Q4 		$1.7M Sell
41,731
-70,357
-63% -$3.73M 0.01% 1407
2022
Q3 		$7.33M Buy
112,088
+66,663
+147% +$4.83M 0.02% 609
2022
Q2 		$2.76M Sell
45,425
-272,949
-86% -$16M 0.01% 1025
2022
Q1 		$20M Buy
318,374
+105,790
+50% +$6.64M 0.06% 386
2021
Q4 		$16.1M Buy
212,584
+207,310
+3,931% +$18.1M 0.03% 564
2021
Q3 		$590K Sell
5,274
-425,751
-99% -$53.5M ﹤0.01% 3097
2021
Q2 		$69.8M Sell
431,025
-707,083
-62% -$86M 0.16% 151
2021
Q1 		$139M Buy
1,138,108
+856,873
+305% +$129M 0.36% 50
2020
Q4 		$43.1M Buy
281,235
+42,724
+18% +$5.05M 0.12% 188
2020
Q3 		$19.9M Buy
238,511
+120,863
+103% +$10.7M 0.07% 298
2020
Q2 		$8.65M Sell
117,648
-111,741
-49% -$6.53M 0.04% 441
2020
Q1 		$9.73M Sell
229,389
-229,617
-50% -$11.9M 0.08% 265
2019
Q4 		$28M Buy
459,006
+362,978
+378% +$19.8M 0.08% 281
2019
Q3 		$3.94M Buy
96,028
+62,628
+188% +$2.99M 0.01% 987
2019
Q2 		$1.57M Sell
33,400
-42,912
-56% -$1.72M 0.01% 1605
2019
Q1 		$2.73M Sell
76,312
-433,260
-85% -$15M 0.01% 1250
2018
Q4 		$14.6M Buy
509,572
+102,478
+25% +$3.56M 0.06% 424
2018
Q3 		$18.1M Buy
407,094
+354,254
+670% +$18.6M 0.05% 446
2018
Q2 		$3.1M Sell
52,840
-51,958
-50% -$2.96M 0.01% 1324
2018
Q1 		$4.79M Buy
104,798
+58,824
+128% +$2.43M 0.02% 974
2017
Q4 		$1.08M Buy
+45,974
New +$874K ﹤0.01% 1916

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

John Overdeck's CRSP Position: Q2 2026 in Review

John Overdeck increased its CRISPR Therapeutics (CRSP) stake by 34% in Q2 2026, buying an estimated $26.6M and bringing the position to 1,988,621 shares worth $108M. The position accounts for 0.08% of the portfolio, ranked #291.

John Overdeck first reported a position in CRSP in Q4 2017 and has held it in 35 quarters since. The position peaked at $139M in Q1 2021. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • John Overdeck held 1,988,621 shares of CRISPR Therapeutics worth $108M as of Q2 2026.
  • John Overdeck bought 505,570 CRISPR Therapeutics shares in Q2 2026, an estimated $26.6M.
  • CRISPR Therapeutics made up 0.08% of John Overdeck's portfolio in Q2 2026, its #291 holding.
  • John Overdeck first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 35 quarters since.
  • John Overdeck's CRISPR Therapeutics position peaked at $139M in Q1 2021.
  • 520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.